| At ARVO 2026, Elisigen presented 52-week Phase 1/2a data demonstrating that a single low-dose administration of its AAV gene therapy NG101 achieved a favorable safety profile while dramatically reducing the need for anti-VEGF injections in patients with wAMD. |
Read Original Article (Korean)
*Note: This link will redirect you to the original source in Korean.